Former US Ambassador to the EU stated that the US president succumbed to Kremlin persuasion regarding personal and business prospects. The diplomat also explained how changes in Congress could impact aid to Kyiv.
Head of the Presidential Office confirmed that all parties adhered to the agreements during the humanitarian mission in Kherson region.
On Sunday, 1 November, hourly power supply restrictions will be implemented in parts of the country's regions from 06:00 to 23:59. The scale of outages will reach 1.5–2.5 stages due to damage to energy infrastructure.
Russia maintains the ban on diesel fuel exports until the end of January, but is preparing an exception mechanism for certain suppliers amid rising export volumes.
Clashes with law enforcement erupted in the Albanian capital during the 19th day of student protests and an opposition action.
Expert Oleksiy Kuts stated that the government is not taking measures to protect state interests in the conflict surrounding the Stynava field, which threatens the budget with losses exceeding one billion hryvnias.
EU High Representative warns that the possible presence of the Russian president at the December summit in Florida could amount to a de facto normalisation of the crimes Russia is committing in Ukraine.
US Secretary of State Marco Rubio stated that the final decision on inviting the President of Ukraine to the December G20 summit will be made by Donald Trump.
The leading player in the Ukrainian pharmaceutical market, Farmak, is preparing for significant organisational changes. Management plans to abandon the two-tier management system in favour of a single-tier model. This entails the complete liquidation of the existing supervisory board and the formation of a board of directors in its place.
Shareholders are to make the final decision on this matter during a remote session of the general meeting scheduled for 30 November.
Farmak Group holds leading positions in the domestic Ukrainian market in monetary terms. The business group is actively engaged in exports, supplying medicines to over 60 countries worldwide. The company’s production facilities are located in Ukraine and Spain.
Particular attention should be paid to the Spanish subsidiary, Farmak International. This plant has obtained a European Union Good Manufacturing Practice (EU GMP) certificate. The document confirms compliance with manufacturing standards for sterile dosage forms, specifically injectable preparations in vials.
The ultimate beneficial owner of Farmak remains Filia Zhebrovska, who controls 80% of the company’s shares.
Financial indicators indicate stable business growth. According to YouControl data, the revenue of the joint-stock company Farmak increased by 23% in 2025 compared to the previous year, 2024, reaching 13.3 billion hryvnia. Net profit also demonstrated positive dynamics, increasing by 24.3% and exceeding 2 billion hryvnia.
Comments
No comments yet. Be the first!